Michael F. Cola

President & Chief Executive Officer at Aevi Genomic Medicine, Inc.

Michael F. Cola

Michael F. Cola

President & Chief Executive Officer at Aevi Genomic Medicine, Inc.

Overview
Career Highlights

Shire Pharmaceuticals, Inc.
Aevi Genomic Medicine, Inc.
Clarient, Inc.

RelSci Relationships

1434

Number of Boards

14

Birthday

1960

Age

59

Relationships
RelSci Relationships are individuals Michael F. Cola likely has professional access to. A relationship does not necessarily indicate a personal connection.

President at Context Therapeutics

Relationship likelihood: Strong

Founder & Chief Medical Officer at Dermira, Inc.

Relationship likelihood: Strong

Director, President & Chief Executive Officer at SAGE Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Bioagilytix Labs LLC

Relationship likelihood: Strong

Founder at Centrexion Therapeutics Corp.

Relationship likelihood: Strong

President & Chief Executive Officer at Regentis Biomaterials Ltd.

Relationship likelihood: Strong

President & Chief Executive Officer at Vanda Pharmaceuticals Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at University City Science Center

Relationship likelihood: Strong

Senior Vice President, Corporate & Business Development at Aevi Genomic Medicine, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Safeguard Scientifics, Inc.

Relationship likelihood: Strong

Paths to Michael F. Cola
Potential Connections via
Relationship Science
You
Michael F. Cola
President & Chief Executive Officer at Aevi Genomic Medicine, Inc.
Education
BA in Biology & Physics

"Ursinus is a remarkable college--student centered, academically rigorous, ambitious, achieving, serious about students in the community--focused, in other words, on the right things."

MS in Biomedical Engineering

Drexel is a comprehensive global research university ranked among the top 100 in the nation. With approximately 25,000 students, Drexel is one of America’s 15 largest private universities. Drexel has built its global reputation on core achievements that include: Leadership in experiential learning through Drexel Co-op. A history of academic technology firsts. Recognition as a model of best practices in translational, use-inspired research. Founded in 1891 in Philadelphia, Drexel now engages with students and communities around the world via: Three Philadelphia campuses and other regional sites. Drexel University Sacramento The Academy of Natural Sciences of Drexel University, the nation’s oldest major natural science museum and research organization. International research partnerships including China and Israel. Drexel Online, one of the oldest and most successful providers of online degree programs. Drexel is one of Philadelphia’s top 10 employers, and a major engine for economic development in the region. Drexel has committed to being the nation’s most civically engaged university, with community partnerships integrated into every aspect of service and academics. Drexel’s ongoing strategic plan, “Transforming the Modern Urban University,” guides the University’s 21st-century trajectory.

Career History
President & Chief Executive Officer
2013 - Current

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

President Vice President
Tenure Unconfirmed

Part of Takeda Pharmaceutical Co., Ltd., Shire Pharmaceuticals LLC is an American company. The firm manufactures pharmaceutical products.

Executive Vice President-Therapeutic Area Business
2005 - 2008

Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986

Boards & Committees
Director
Current

Ventaira Pharmaceuticals Inc. develops aerosol devices. It offers inhaled drugs, including fentanyl for the treatment of breakthrough pain and salmeterol/flucticasone for asthma. The company was founded in April 2000 and is headquartered in Columbus, OH.

Chairman
2004 - 2004

SFN Group, Inc. provides temporary personnel services to businesses professional and health care facilities. The company was founded in 1946 and is headquartered in Woburn, MA.

Director
2003 - 2006

Clarient, Inc. provides cancer diagnostic testing services. It offers oncology diagnostic testing services to community pathologists, oncologists, biopharmaceutical companies, and researchers. The company was founded in 1993 and is headquartered in Aliso Viejo, CA.

Trustee
Current

"Ursinus is a remarkable college--student centered, academically rigorous, ambitious, achieving, serious about students in the community--focused, in other words, on the right things."

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$5,000 - $10K
2011

"Ursinus is a remarkable college--student centered, academically rigorous, ambitious, achieving, serious about students in the community--focused, in other words, on the right things."

Political Donations
$1,000
2012

Senator from Pennsylvania

$500
2008

Former President of United States

Transactions
Details Hidden

Aevi Genomic Medicine, Inc. raised money in a private placement transaction

Details Hidden

Aevi Genomic Medicine, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael F. Cola. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael F. Cola's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael F. Cola.